WO1999036068A1 - Activateurs des canaux de potassium - Google Patents
Activateurs des canaux de potassium Download PDFInfo
- Publication number
- WO1999036068A1 WO1999036068A1 PCT/JP1999/000103 JP9900103W WO9936068A1 WO 1999036068 A1 WO1999036068 A1 WO 1999036068A1 JP 9900103 W JP9900103 W JP 9900103W WO 9936068 A1 WO9936068 A1 WO 9936068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cyano
- alkoxy
- substituted
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
Definitions
- alkylene examples include linear or branched ones having 1 to 4 carbon atoms, for example, the following.
- Preferred examples of the compound [1] of the present invention include, for example, R 1 is hydrogen, R 2 is NH 2 , pyrrolidino or methyl, R 3 is cyano, R 4 is hydrogen or methyl, and q is 0.
- A is a compound which is a substituted or unsubstituted aryl or an optionally substituted aromatic heterocyclic group.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/582,743 US6353016B1 (en) | 1998-01-14 | 1999-01-13 | Potassium channel activators |
CA002316853A CA2316853A1 (en) | 1998-01-14 | 1999-01-13 | Potassium channel activators |
DE69925250T DE69925250T2 (de) | 1998-01-14 | 1999-01-13 | Aktivatoren der kalium-kanäle |
KR1020007007727A KR20010034114A (ko) | 1998-01-14 | 1999-01-13 | 칼륨 채널 활성화제 |
AU18902/99A AU1890299A (en) | 1998-01-14 | 1999-01-13 | Potassium channel activators |
EP99900312A EP1057485B1 (en) | 1998-01-14 | 1999-01-13 | Potassium channel activators |
AT99900312T ATE295166T1 (de) | 1998-01-14 | 1999-01-13 | Aktivatoren der kalium-kanäle |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/5613 | 1998-01-14 | ||
JP561398 | 1998-01-14 | ||
JP10/50888 | 1998-03-03 | ||
JP5088898 | 1998-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999036068A1 true WO1999036068A1 (fr) | 1999-07-22 |
Family
ID=26339581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/000103 WO1999036068A1 (fr) | 1998-01-14 | 1999-01-13 | Activateurs des canaux de potassium |
Country Status (10)
Country | Link |
---|---|
US (1) | US6353016B1 (ja) |
EP (1) | EP1057485B1 (ja) |
KR (1) | KR20010034114A (ja) |
CN (1) | CN1162151C (ja) |
AT (1) | ATE295166T1 (ja) |
AU (1) | AU1890299A (ja) |
CA (1) | CA2316853A1 (ja) |
DE (1) | DE69925250T2 (ja) |
RU (1) | RU2204390C2 (ja) |
WO (1) | WO1999036068A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070221A1 (fr) * | 2000-03-21 | 2001-09-27 | Nippon Shinyaku Co., Ltd. | Preparations orales a liberation prolongee |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1303502A2 (en) * | 2000-07-06 | 2003-04-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Tetrahydrobenzothiazole analogues as neuroprotective agents |
TWI239952B (en) * | 2001-03-14 | 2005-09-21 | Nippon Shinyaku Co Ltd | Stable crystals of pyrrole compound |
CA2537746A1 (en) * | 2003-09-04 | 2005-03-17 | Poseidon Pharmaceuticals A/S | Erg channel openers for the treatment of cardiac arrhythmias |
JP4703649B2 (ja) * | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | 薬学的因子としてのピロール誘導体 |
US8278466B2 (en) | 2008-04-28 | 2012-10-02 | Janssen Pharmaceutica Nv | Benzocycloheptane and benzoxepine derivatives |
GB201107176D0 (en) * | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05246980A (ja) * | 1991-12-26 | 1993-09-24 | Mitsubishi Kasei Corp | β−オキソ−β−ベンゼンプロパンチオアミド誘導体 |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1998002430A1 (en) * | 1996-07-11 | 1998-01-22 | Pfizer Pharmaceuticals Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3439249B2 (ja) * | 1993-11-18 | 2003-08-25 | 三和生薬株式会社 | 新規なピロール型化合物及び発毛・育毛促進剤 |
US5998459A (en) * | 1995-06-07 | 1999-12-07 | Nippon Shinyaku Co Ltd | Pyrrole derivatives and medicinal composition |
WO1999061016A1 (en) * | 1998-05-27 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Cyclooxygenase-2 inhibitors |
-
1999
- 1999-01-13 RU RU2000121069/14A patent/RU2204390C2/ru not_active IP Right Cessation
- 1999-01-13 EP EP99900312A patent/EP1057485B1/en not_active Expired - Lifetime
- 1999-01-13 US US09/582,743 patent/US6353016B1/en not_active Expired - Fee Related
- 1999-01-13 DE DE69925250T patent/DE69925250T2/de not_active Expired - Fee Related
- 1999-01-13 CN CNB998021067A patent/CN1162151C/zh not_active Expired - Fee Related
- 1999-01-13 KR KR1020007007727A patent/KR20010034114A/ko not_active Application Discontinuation
- 1999-01-13 AT AT99900312T patent/ATE295166T1/de not_active IP Right Cessation
- 1999-01-13 CA CA002316853A patent/CA2316853A1/en not_active Abandoned
- 1999-01-13 AU AU18902/99A patent/AU1890299A/en not_active Abandoned
- 1999-01-13 WO PCT/JP1999/000103 patent/WO1999036068A1/ja active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05246980A (ja) * | 1991-12-26 | 1993-09-24 | Mitsubishi Kasei Corp | β−オキソ−β−ベンゼンプロパンチオアミド誘導体 |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1998002430A1 (en) * | 1996-07-11 | 1998-01-22 | Pfizer Pharmaceuticals Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070221A1 (fr) * | 2000-03-21 | 2001-09-27 | Nippon Shinyaku Co., Ltd. | Preparations orales a liberation prolongee |
Also Published As
Publication number | Publication date |
---|---|
KR20010034114A (ko) | 2001-04-25 |
CN1162151C (zh) | 2004-08-18 |
EP1057485A1 (en) | 2000-12-06 |
CN1288377A (zh) | 2001-03-21 |
RU2204390C2 (ru) | 2003-05-20 |
CA2316853A1 (en) | 1999-07-22 |
DE69925250D1 (de) | 2005-06-16 |
AU1890299A (en) | 1999-08-02 |
EP1057485A4 (en) | 2001-05-09 |
EP1057485B1 (en) | 2005-05-11 |
US6353016B1 (en) | 2002-03-05 |
DE69925250T2 (de) | 2006-02-23 |
ATE295166T1 (de) | 2005-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69831877T2 (de) | Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide | |
CN110256421A (zh) | Kras-g12c抑制剂 | |
US4623646A (en) | PAF-antagonistic diazepines, methods of use | |
US10442794B2 (en) | Processes for preparing pyridine carboxamide derivatives | |
AU704857B2 (en) | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists | |
LT3918B (en) | 2,4- and 2,5- substituted pyridin-n-oxides, methods for the production thereof, pharmaceutical compositions and preparation the same | |
WO1999036068A1 (fr) | Activateurs des canaux de potassium | |
US5185360A (en) | Dihydroindenoindole compounds and methods for using the same | |
US6197796B1 (en) | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative | |
KR20030016222A (ko) | 수술후 스트레스 예방ㆍ치료제 | |
MXPA06004434A (es) | Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos. | |
EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
ES2203867T3 (es) | Derivados de benzopiranos sustituidos con sulfonamidas, procedimientos para su preparacion, su utilizacion como medicamento, asi como formulaciones farmaceuticas que los contienen. | |
EP0718290A1 (en) | Carboxyalkyl heterocyclic derivatives | |
WO1999061016A1 (en) | Cyclooxygenase-2 inhibitors | |
JP3535207B2 (ja) | 抗ガン剤及びgrpレセプター拮抗剤 | |
WO1992006956A1 (en) | Indenoindole compounds | |
EP1219614A1 (en) | Benzene sulfonamides as PDE-V inhibitors for the use against erectile dysfunction | |
JP3365732B2 (ja) | 脳再灌流障害治療剤 | |
KR19990007796A (ko) | 혈관 신생 억제제 | |
AU732722B2 (en) | 2-{4-{4-(4,5-dichloro-2- methylimidazol-1-yl)butyl} -1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use | |
US5106859A (en) | Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient | |
JPS6216417A (ja) | 虚血性心疾患・不整脈治療・予防剤 | |
MXPA00006647A (en) | Potassium channel activators | |
US20020151552A1 (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99802106.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BG BR CA CH CN CZ DE DK ES FI GB HU ID JP KR LK LT LU MN MX NO NZ PL PT RU SE SG SI SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2316853 Country of ref document: CA Ref document number: 2316853 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09582743 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/006647 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007007727 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999900312 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999900312 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007007727 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007007727 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999900312 Country of ref document: EP |